Total Payments
$110,300
2024 Payments
$28,271
Companies
25
Transactions
507
Medicare Patients
3,174
Medicare Billing
$522,665
Payment Breakdown by Category
Other$84,143 (76.3%)
Travel$15,533 (14.1%)
Food & Beverage$9,633 (8.7%)
Consulting$600.00 (0.5%)
Education$391.17 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $84,143 | 52 | 76.3% |
| Travel and Lodging | $15,533 | 37 | 14.1% |
| Food and Beverage | $9,633 | 403 | 8.7% |
| Consulting Fee | $600.00 | 1 | 0.5% |
| Education | $391.17 | 14 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $105,615 | 252 | $0 (2024) |
| Insmed, Inc. | $888.05 | 40 | $0 (2024) |
| Merck Sharp & Dohme LLC | $717.32 | 52 | $0 (2024) |
| ViiV Healthcare Company | $662.11 | 47 | $0 (2024) |
| Astellas Pharma US Inc | $427.60 | 23 | $0 (2024) |
| Shionogi Inc | $403.35 | 16 | $0 (2024) |
| La Jolla Pharmaceutical Company | $345.32 | 11 | $0 (2024) |
| Melinta Therapeutics, LLC | $303.51 | 18 | $0 (2024) |
| Paratek Pharmaceuticals, Inc. | $198.35 | 12 | $0 (2024) |
| ABBVIE INC. | $115.93 | 7 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $28,271 | 112 | Gilead Sciences, Inc. ($27,288) |
| 2023 | $30,724 | 103 | Gilead Sciences, Inc. ($29,914) |
| 2022 | $17,153 | 78 | Gilead Sciences, Inc. ($16,511) |
| 2021 | $14,938 | 68 | Gilead Sciences, Inc. ($14,190) |
| 2020 | $4,941 | 21 | Gilead Sciences, Inc. ($4,703) |
| 2019 | $13,870 | 100 | Gilead Sciences, Inc. ($12,936) |
| 2018 | $403.81 | 25 | Astellas Pharma US Inc ($122.99) |
All Payment Transactions
507 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | PFIZER INC. | PANZYGA (Biological), CUTAQUIG | Food and Beverage | In-kind items and services | $15.52 | General |
| Category: IMMUNOLOGY;INFLAMMATION | ||||||
| 12/16/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.70 | General |
| 12/10/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $400.00 | General |
| Category: HIV | ||||||
| 12/09/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $21.09 | General |
| Category: Respiratory | ||||||
| 12/05/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.26 | General |
| 12/04/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.81 | General |
| 12/02/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $17.78 | General |
| Category: HIV | ||||||
| 11/21/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $435.00 | General |
| Category: COVID-19 | ||||||
| 11/18/2024 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $14.42 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/13/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $26.30 | General |
| 11/07/2024 | Merck Sharp & Dohme LLC | DELSTRIGO (Drug) | Food and Beverage | In-kind items and services | $22.91 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/05/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.48 | General |
| 10/30/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.82 | General |
| 10/30/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $15.97 | General |
| 10/29/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Orbactiv, Kimyrsa | Food and Beverage | In-kind items and services | $23.97 | General |
| Category: ANTIFUNGALS | ||||||
| 10/23/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $19.63 | General |
| Category: Infectious Diseases | ||||||
| 10/22/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $34.06 | General |
| 10/21/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $26.89 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 10/16/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.06 | General |
| 10/10/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $22.85 | General |
| Category: Infections and Infectious Diseases | ||||||
| 09/23/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Orbactiv, Kimyrsa | Food and Beverage | In-kind items and services | $23.93 | General |
| Category: ANTIFUNGALS | ||||||
| 09/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.23 | General |
| 09/18/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Travel and Lodging | In-kind items and services | $52.56 | General |
| Category: COVID-19 | ||||||
| 09/18/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: COVID-19 | ||||||
| 09/18/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $16.05 | General |
| Category: COVID-19 | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 746 | 32,386 | $446,519 | $123,233 |
| 2022 | 12 | 650 | 48,933 | $396,424 | $118,860 |
| 2021 | 15 | 845 | 28,640 | $369,347 | $131,568 |
| 2020 | 15 | 933 | 57,577 | $478,740 | $149,003 |
Total Patients
3,174
Total Services
167,536
Medicare Billing
$522,665
Procedure Codes
55
All Medicare Procedures & Services
55 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 166 | 707 | $128,205 | $42,151 | 32.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 100 | 276 | $60,700 | $25,731 | 42.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 126 | 140 | $54,700 | $16,637 | 30.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 86 | 245 | $49,000 | $11,174 | 22.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 50 | 122 | $28,210 | $10,899 | 38.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 46 | 52 | $15,900 | $5,111 | 32.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 14 | 28 | $15,460 | $4,259 | 27.5% |
| J1335 | Injection, ertapenem sodium, 500 mg | Office | 2023 | 30 | 184 | $27,600 | $1,926 | 7.0% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 22 | 74 | $11,840 | $1,559 | 13.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 25 | 28 | $4,400 | $1,434 | 32.6% |
| J0878 | Injection, daptomycin, 1 mg | Office | 2023 | 28 | 29,700 | $32,580 | $1,182 | 3.6% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 14 | 22 | $3,380 | $843.26 | 24.9% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 39 | 808 | $14,544 | $327.32 | 2.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 149 | 684 | $78,660 | $36,882 | 46.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 90 | 239 | $35,850 | $22,048 | 61.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 112 | 133 | $43,245 | $19,513 | 45.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 65 | 172 | $26,660 | $13,069 | 49.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 68 | 251 | $50,200 | $12,316 | 24.5% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 21 | 33 | $12,210 | $5,407 | 44.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 27 | 27 | $6,750 | $2,684 | 39.8% |
| J1335 | Injection, ertapenem sodium, 500 mg | Office | 2022 | 18 | 120 | $18,000 | $1,864 | 10.4% |
| J0878 | Injection, daptomycin, 1 mg | Office | 2022 | 26 | 46,250 | $97,125 | $1,859 | 1.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 23 | 25 | $2,500 | $1,703 | 68.1% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 13 | 51 | $8,160 | $1,140 | 14.0% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2022 | 38 | 948 | $17,064 | $375.37 | 2.2% |
About Dr. David Dougherty, M.D
Dr. David Dougherty, M.D is a Infectious Disease healthcare provider based in Lexington, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/30/2013. The National Provider Identifier (NPI) number assigned to this provider is 1104261445.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Dougherty, M.D has received a total of $110,300 in payments from pharmaceutical and medical device companies, with $28,271 received in 2024. These payments were reported across 507 transactions from 25 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($84,143).
As a Medicare-enrolled provider, Dougherty has provided services to 3,174 Medicare beneficiaries, totaling 167,536 services with total Medicare billing of $522,665. Data is available for 4 years (2020–2023), covering 55 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Other Specialties Infectious Disease, Student in an Organized Health Care Education/Training Program
- Location Lexington, KY
- Active Since 04/30/2013
- Last Updated 09/26/2018
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1104261445
Products in Payments
- Veklury (Drug) $46,841
- Biktarvy (Drug) $37,967
- Descovy (Drug) $8,541
- Arikayce (Drug) $888.05
- DOVATO (Drug) $555.50
- Fetroja (Drug) $403.35
- DIFICID (Drug) $303.13
- XERAVA (Drug) $210.16
- NUZYRA (Drug) $198.35
- Cresemba (Drug) $155.62
- XACDURO (Drug) $151.51
- ZERBAXA (Drug) $149.00
- Vabomere (Drug) $128.90
- PIFELTRO (Drug) $116.34
- TEFLARO (Drug) $112.91
- Rezzayo (Drug) $110.19
- AMBISOME (Drug) $109.31
- ISENTRESS (Drug) $107.87
- DALVANCE (Drug) $100.22
- Xerava (Drug) $69.69
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Lexington
Daniel Rodrigue, Md, MD
Infectious Disease — Payments: $50,659
Infectious Disease $50,659
Charles Rose
Infectious Disease — Payments: $42,996
Infectious Disease $42,996
Dr. Marty Allen, M.d, M.D
Infectious Disease — Payments: $39,505
Infectious Disease $39,505
John Meek, Md, MD
Infectious Disease — Payments: $13,273
Infectious Disease $13,273
Mark Dougherty, Md, MD
Infectious Disease — Payments: $12,643
Infectious Disease $12,643
Dr. Andrea Banks, Md, MD
Infectious Disease — Payments: $9,877
Infectious Disease $9,877